Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Armitage

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|June 15, 2007
The safety of statins in clinical practiceJane Armitage
Cardiovascular Drugs and Therapy|March 26, 2003
Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trialsRobert Clarke, Jane Armitage
Current Opinion in Lipidology|July 10, 2004
Cardiovascular outcomes among participants with diabetes in the recent large statin trialsJane Armitage, Louise Bowman
Atherosclerosis|January 2, 2016
Management of residual risk after statin therapyChristina Reith, Jane Armitage
Current Opinion in Lipidology|June 27, 2012
LDL cholesterol targets--how low to go?Richard Bulbulia, Jane Armitage
Current Atherosclerosis Reports|January 10, 2013
Does the benefit from statin therapy extend beyond 5 years?Richard Bulbulia, Jane Armitage
Seminars in Vascular Medicine|October 14, 2005
Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular riskLouise Bowman, Jane Armitage
International Journal of Clinical Practice|February 8, 2002
The MRC/BHF Heart Protection Study: preliminary resultsRory Collins, Richard Peto, Jane Armitage
Current Opinion in Lipidology|October 15, 2014
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?Jemma C Hopewell, Christina Reith, Jane Armitage
Journal of the American College of Cardiology|February 2, 2019
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the WeekJane Armitage, Michael V Holmes, David Preiss
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|June 15, 2007
The safety of statins in clinical practiceJane Armitage
Cardiovascular Drugs and Therapy|March 26, 2003
Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trialsRobert Clarke, Jane Armitage
Current Opinion in Lipidology|July 10, 2004
Cardiovascular outcomes among participants with diabetes in the recent large statin trialsJane Armitage, Louise Bowman
Atherosclerosis|January 2, 2016
Management of residual risk after statin therapyChristina Reith, Jane Armitage
Current Opinion in Lipidology|June 27, 2012
LDL cholesterol targets--how low to go?Richard Bulbulia, Jane Armitage
Current Atherosclerosis Reports|January 10, 2013
Does the benefit from statin therapy extend beyond 5 years?Richard Bulbulia, Jane Armitage
Seminars in Vascular Medicine|October 14, 2005
Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular riskLouise Bowman, Jane Armitage
International Journal of Clinical Practice|February 8, 2002
The MRC/BHF Heart Protection Study: preliminary resultsRory Collins, Richard Peto, Jane Armitage
Current Opinion in Lipidology|October 15, 2014
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?Jemma C Hopewell, Christina Reith, Jane Armitage
Journal of the American College of Cardiology|February 2, 2019
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the WeekJane Armitage, Michael V Holmes, David Preiss
Pageof 11